We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Protagonist Therapeutics Inc
14 own
13 watching
Current Price
$14.06
$0.77
(5.79%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
691.73M
52-Week High
30.42
52-Week Low
6.91
Average Volume
1.07M
Dividend Yield
--
P/E Ratio
--
Market Capitalization691.73M52-Week High30.4252-Week Low6.91Average Volume1.07MDividend Yield--P/E Ratio--What does the Protagonist Therapeutics Inc do?
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Read More
How much money does Protagonist Therapeutics Inc make?
News & Events about Protagonist Therapeutics Inc.
PR Newswire
4 months ago
Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro? Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro? PR Newswire NEW YORK, Oct. 3, 2022 NEW YORK, Oct. 3, 2022 /PRNewswire...
Ticker Report
8 months ago
Protagonist Therapeutics (NASDAQ:PTGX Get Rating) was downgraded by StockNews.com from a hold rating to a sell rating in a note issued to investors on Friday. Several other equities analysts have also recently issued reports on the company. Piper Sandler decreased...
Zolmax
8 months ago
Protagonist Therapeutics (NASDAQ:PTGX Get Rating) was downgraded by StockNews.com from a hold rating to a sell rating in a note issued to investors on Friday. Several other equities analysts have also recently issued reports on the company. Piper Sandler decreased their price objective on ...
Ticker Report
8 months ago
Northern Trust Corp lessened its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX Get Rating) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 455,411 shares of the company&#...
Zolmax
8 months ago
Northern Trust Corp cut its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX Get Rating) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 455,411 shares of the companys stock after ...
Frequently Asked Questions
Frequently Asked Questions
What is Protagonist Therapeutics Inc share price today?
Can Indians buy Protagonist Therapeutics Inc shares?
How can I buy Protagonist Therapeutics Inc shares from India?
Can Fractional shares of Protagonist Therapeutics Inc be purchased?
What are the documents required to start investing in Protagonist Therapeutics Inc stocks?
What is today’s traded volume of Protagonist Therapeutics Inc?
What is today’s market capitalisation of Protagonist Therapeutics Inc?
What is the 52-Week High and Low Range of Protagonist Therapeutics Inc?
What percentage is Protagonist Therapeutics Inc down from its 52-Week High?
What percentage is Protagonist Therapeutics Inc up from its 52-Week Low?
Current Price
$14.06
$0.77
(5.79%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.